PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to induce an immune response against prostate cancer.
PROVENGE Full Prescribing Information
Print page
Email page